[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ami\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ami":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,74,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100620809","phase-2-prevention-of-reperfusion-injury-outcomes-through-effective-cardioprotection-targeting-myocardial-infarction-100620809",false,"NCT07362446","Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction","A Randomised, Double-Blind, Placebo-Controlled, Study of Xolatryp in Patients Presenting With STEMI Undergoing Primary PCI","PROTECT-MI","Inclusion Criteria:\n\n* Have provided informed consent.\n* Male patients aged 40 to 75 years of age.- Female patients aged 55 to 75 years of age, or women aged 40 to 55 years that have no possibility of being pregnant.\n* Patient presents with first-time STEMI, scheduled to undergo primary PCI within 6 h of symptom onset and anticipated door to balloon time \\\u003C 2 h.\n* In combination with symptoms consistent with acute MI, patient must demonstrate ST-elevation at the J-point in two contiguous leads.\n* Hemodynamically stable including: systolic BP ≥ 90 mmHg, HR 50-120 bpm.\n* Killip Class I or II.\n* Oxygen saturation ≥ 92% on room air or low-flow oxygen.\n* No ongoing VT\u002FVF at enrolment.\n* Male participants with female partners of child-bearing potential must be ready and able to use highly effective methods of birth control for at least 7 days following IP administration.\n\nExclusion Criteria:\n\n* History or ECG evidence of myocardial infarction or cardiomyopathy.\n* Prior major cardiac surgery, including but not limited to coronary artery bypass graft surgery (CABG).\n* Known contraindication to CMR (e.g. pacemakers, cochlear implants, aneurism clips, claustrophobia, allergy to contrast medium).\n* History of clinically significant renal impairment requiring dialysis or an estimated glomerular filtration rate \\\u003C30 mL\u002Fmin.\n* Estimated or known body weight \\\u003C 50 kg, \\> 120 kg at screening.\n* Concurrent enrolment in another investigational device or drug trial, or less than 30 days or 5 half-lives of investigational device or drug (whichever is longer), since ending another investigational device or drug trial(s) or receiving other investigational treatment(s). Patients who are participating in non-interventional, purely observational trials can be included.\n* Life expectancy of less than 1 year due to non-cardiac pathology in the opinion of the Investigator.\n* Any condition or significant clinical abnormality identified at the time of screening that in the judgment of the Investigator or any sub-Investigator would preclude safe completion of the study.\n* Known history of hypersensitivity to the investigational drug, or excipients, or do not want to be exposed to soy or egg (including products and derivatives).","ALL","40 Years","75 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This study is open to adults with ST elevation myocardial infarction (heart attack) undergoing primary percutaneous coronary intervention (PCI). The purpose of this study is to determine whether a medicine called Xolatryp is safe and effective in improving cardiac outcomes. One dose of Xolatryp will be tested in this study.\n\nParticipants are put into two groups randomly, which means by chance. One group receives a single 6-hour continuous intravenous infusion of Xolatryp and one group receives placebo. Participants are in the study for about 30 days.\n\nPlacebo infusion looks like Xolatryp but do not contain any medicine. Participants are followed up via telephone and there is one visit to the study site on day 30.\n\nHeart health is assessed based on the analysis of blood samples, which are collected at the study site, via electrocardiogram (ECG), echocardiogram and cardiac magnetic resonance (CMR) imaging. At the end of the study, the results are compared between the two groups. During the study, the doctors also regularly check the general health of the participants.",[28,29,30,31],"Myocardial Infarction","Reperfusion Injury","AMI","STEMI (ST Elevation MI)",[33,34],"STEMI","PCI","RECRUITING","2026-06-29",{"date":38,"type":39},"2026-07-01","ACTUAL",{"date":41,"type":39},"2026-04-22",{"date":43,"type":22},"2027-09-30",{"name":45,"class":46},"Nyrada Pty Ltd","INDUSTRY",7,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":59,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100549767","supersaturated-oxygen-comprehensive-observational-registry-100549767","NCT06438315","SuperSaturated Oxygen Comprehensive Observational Registry","SSCORE","Subjects screened for either the Prospective Control Cohort or the SSO2 Treated (On-Label) Cohorts must meet ALL the following baseline criteria:\n\nPatients must be ≥ 18 years and ≤ 80 years of age\n\nPresentation with AMI and successful revascularization of the infarct-related artery with PCI\n\nThe subject or their legally authorized representative has been informed of the nature of the study, agrees to its provisions and has been provided and signed written informed consent, approved by the appropriate Institutional Review Board (IRB)\n\nTreatment with SSO2 Therapy will be up to the physician's discretion and the decision will be made prior to enrollment in the study. Any subject that is treated with SSO2 Therapy and meets the baseline criteria should be invited to participate in the study.\n\nSubjects who are in the Prospective Control Cohort as well as subjects enrolled in the SSO2 Treated On-Label Cohort must meet these additional criteria:\n\nThe primary culprit lesion must be in the left anterior descending (LAD) coronary artery\n\nSuccessful primary PCI within 6 hours of symptom onset (defined as persistent symptoms that caused the patient to pursue medical care), as documented by \\\u003C50% diameter residual angiographic stenosis and Thrombolysis In Myocardial Infarction (TIMI) Grades 2 or 3 flow in the target vessel\n\nNo major complications such as presence of post-PCI dissection or perforation, serious bleeding, presence of cardiogenic shock (including the use of intra-aortic balloon pump (IABP) or mechanical circulatory support (MCS)) before the end of PCI procedure\n\nNot pregnant or nursing\n\nExclusion Criteria\n\nSubjects will be excluded if they meet any of the following criteria:\n\nLife expectancy of less than 2 years\n\nNo access to medical records from either the index hospitalization or subsequent outpatient visits\n\nCurrently participating in an interventional drug or device trial\n\ncMRI Sub-Study\n\nAt qualifying sites that can perform cMRI scans, subjects who meet the following inclusion and exclusion criteria will be considered for the cMRI sub-study.\n\ncMRI Inclusion Criteria\n\nSubjects will be included in the cMRI sub-study must meet all these criteria:\n\nMeet all the inclusion and exclusion criteria for the overall study\n\nConsent during index hospitalization to participate in the main study\n\ncMRI Exclusion Criteria\n\nSubjects will be excluded from the sub-study if they are contraindicated to MRI, including any of the following:\n\nNon-MRI compatible cardiac pacemaker or implantable defibrillator; Non-MRI compatible aneurysm clip or other metallic implants; Neural Stimulator (i.e., TENS unit); Any implanted or magnetically activated device (insulin pump); Any type of non-MRI compatible ear implant; Metal shavings in the orbits; Any indwelling metallic foreign body, shrapnel, or bullet; Any condition contraindicating MRI, including claustrophobia; Inability to follow breath-hold instructions or to maintain a breath-hold for \\>15 seconds; and Known hypersensitivity or contraindication to gadolinium contrast.","18 Years","80 Years",{"count":58,"type":22},1000,"2 Years","OBSERVATIONAL","The SuperSaturated Oxygen Comprehensive Observational Registry (SSCORE) registry, a prospectively designed observational study, aims to evaluate the clinical utility, infarct size reduction, and cost-effectiveness of SSO2 Therapy versus PCI alone among patients with anterior AMI in routine clinical practice.",[63,30],"STEMI - ST Elevation Myocardial Infarction","2026-05-12",{"date":66,"type":39},"2026-05-15",{"date":68,"type":39},"2024-08-13",{"date":70,"type":22},"2029-03-31",{"name":72,"class":46},"TherOx",25,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":106},"100497961","phase-3-dapagliflozine-to-attenuate-cardiac-remodeling-after-acute-myocardial-infarction-100497961","NCT05764057","DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction","DAPAPROTECTOR","Inclusion Criteria:\n\n* Age ≥18 years;\n* STEMI (e.g., ST elevation above the J-point of ≥0.1 millivolt in ≥two contiguous leads or left bundle branch block) or very high-risk NSTEMI (e.g., dynamic ECG changes or ongoing chest pain or acute heart failure or hemodynamic instability independent of ECG changes or life-threatening ventricular arrhythmias) with LV dysfunction (LVEF ≤45%); after completion of PCI or angiography procedure\n* eGFR ≥ 25 mL\u002FMin per 1.73m²;\n* Systolic blood pressure (SBP) before first dosing \\>100 mmHg and\u002For Diastolic blood pressure (DBP) \\>70 mmHg before first dosing;\n* Ability to provide written informed consent and willing to participate in the 6-month follow-up period.\n* Affiliation to a national health care system (AME are not allowed).\n\nExclusion Criteria:\n\n* Cardiogenic shock (SBP \\\u003C90 mmHg with clinical signs of low output or patients requiring inotropic agents) at randomization;\n* Referred to surgery for coronary artery bypass grafting (CABG) or treatment of acute complications (e.g. ventricular septal rupture);\n* Any other form of diabetes than diabetes type 2\n* History of diabetic ketoacidosis (DKA); Known contra-indication to SGLT-2 inhibitors (hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption);\n* \\>1 episode of severe hypoglycemia within the last 6 months under treatment with insulin or sulfonylurea;\n* Acute symptomatic urinary tract infection (UTI) or genital infection at the time of randomization;\n* Concomitant treatment (and\u002For within the 4 weeks prior to the baseline visit) with any SGLT-2 inhibitor (dapagliflozin, canagliflozin, empagliflozin)\n* Echocardiographic examination of insufficient quality to permit adequate analysis of the study end-points.\n* Impossibility to evaluate cardiac remodeling using TTE (e.g., pacemaker or defibrillator …);\n* Atrial fibrillation rhythm at randomization;\n* Life expectancy \\\u003C6 month;\n* Known pregnancy at time of randomization;\n* Breastfeeding women\n* Females of childbearing potential without adequate contraceptive methods (i.e. sterilization, intrauterine device, vasectomized partner; or medical history of hysterectomy)\n* Current participation in another interventional trial. Patients under guardianship or curatorship",{"count":82,"type":22},450,[84],"PHASE3","Recent clinical trials have proven the cardiovascular benefits of new medications for patients with heart failure with reduced ejection fraction (HFrEF), especially sodium-glucose co-transporter 2 (SGLT2) inhibitors. There are no existing randomized clinical trials evaluating the efficacy and safety of dapagliflozin (nor any other SGLT2-inhibitor) to limit cardiac remodeling in patients with acute myocardial infarction (AMI) and left ventricular (LV) dysfunction.\n\nPreventing cardiac remodeling, an established predictor of subsequent heart failure (HF) and cardiovascular death, is likely to translate into benefit in reducing clinical events in post-MI patients.",[30,33,87,88],"NSTEMI","Left Ventricular Dysfunction",[90,91,92,93,94,95],"Acute myocardial infarction","Left ventricular dysfunction","Dapagliflozin","Transthoracic echocardiography","Cardiac remodeling","Cardiovascular Intensive Care Unit (CICU)","2025-12-12",{"date":98,"type":39},"2025-12-19",{"date":100,"type":39},"2023-06-12",{"date":102,"type":22},"2026-10-12",{"name":104,"class":105},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":19,"enrollmentInfo":114,"targetDuration":116,"studyType":60,"phases":4,"briefSummary":117,"conditions":118,"keywords":119,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":106},"100603601","high-frequency-qrs-for-predicting-microvascular-dysfunction-and-adverse-events-after-pci-in-acute-myocardial-infarction-100603601","NCT07138638","High-Frequency QRS for Predicting Microvascular Dysfunction and Adverse Events After PCI in Acute Myocardial Infarction","High-Frequency QRS for Predicting Microvascular Dysfunction and Adverse Events After PCI in Acute Myocardial Infarction: A Prospective, Multicenter Cohort Study","Inclusion Criteria:\n\n* Aged 18 to 75 years (inclusive)\n\nDiagnosed with acute myocardial infarction (AMI, including STEMI and NSTEMI) and underwent successful emergency PCI\n\nVoluntarily participated and provided written informed consent\n\nExclusion Criteria:\n\n* History of prior myocardial infarction or chronic heart failure\n\nQRS duration \\>120 ms (including paced rhythm, WPW syndrome, bundle branch block, or left ventricular hypertrophy with repolarization abnormalities)\n\nStructural heart disease (congenital heart disease, cardiomyopathy, aortic dissection, etc.)\n\nPersistent atrial fibrillation or malignant arrhythmias\n\nHistory of cerebral hemorrhage or ischemic stroke within 1 month\n\nProlonged cardiopulmonary resuscitation or requiring advanced life support (IABP\u002FECMO, etc.)\n\nScheduled for imminent surgery with anticipated inability to complete HF-QRS assessment\n\nOther life-threatening conditions including: Severe hepatic or renal dysfunction;Uncontrolled systemic diseases;Hematologic disorders;Active infections;Malignancy with life expectancy \\\u003C1 year Other investigator-determined exclusionary conditions:Pregnancy;Concurrent participation in other clinical trials\n\nRefusal to participate in the clinical study",{"count":115,"type":22},1112,"1 Year","This observational study aimed to investigate the prognostic value of high-frequency QRS (HF-QRS) in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI), as well as its potential role in diagnosing microvascular dysfunction. The main question it aims to answer is:\n\n1. Whether HF-QRS could serve as an effective tool for early identification of high-risk AMI patients and prognosis prediction;\n2. Whether HF-QRS provides auxiliary diagnostic value for post-AMI microvascular dysfunction.\n\nParticipants underwent HF-QRS assessment and were prospectively followed for 1 year to record the incidence of major adverse cardiovascular events (MACE).",[30],[120,121,122,123],"Acute Myocardial Infarction","High-Frequency QRS","prediction model","Microvascular Dysfunction","NOT_YET_RECRUITING","2025-08-16",{"date":127,"type":39},"2025-08-24",{"date":129,"type":22},"2025-08",{"date":131,"type":22},"2027-12",{"name":133,"class":105},"The Affiliated Hospital of Xuzhou Medical University"]